Citations

Clear

1893 citation(s) found for "Wu, Kenneth".

2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Neogi, Tuhina , Dalbeth, Nicola , Fransen, Jaap , Schumacher, H. Ralph, Berendsen, Dianne, Brown, Melanie , Edwards, N. Lawrence, Lioté, Frédéric , Naden, Raymond P., Nuki, George, Ogdie, Alexis , Pérez-Ruiz, Fernando , Singh, Jasvinder A. , Sundy, John S., Tausche, Anne‐Kathrin , Vaquez‐Mellado, Janitzia, Yarows, Steven A. , Jansen, Tim , Choi, Hyon K. , Janssen, M. , Saag, Kenneth G. , Taylor, William John , Singh, Jasvinder A , Neogi, Tuhina , Ogdie, Alexis

Mayo Clinic

Arthritis & Rheumatology | September 10, 2015 | Volume: 67 | Issue: 10 | Pages: 2557-2568

10.1002/art.39254 | PMID 26352873 Get It

Objective Existing criteria for the classification of gout have suboptimal sensitivity and/or specificity, and were developed at a time when advanced imaging was not available. The current effort was undertaken to develop new classification criteria for gout. Methods An international group of investigators, supported by the American College of Rheumatology and the European League Against Rheumatism, conducted a systematic review of the literature on advanced imaging of gout, a diagnostic study in which the presence of monosodium urate monohydrate (MSU) crystals in synovial fluid or tophus was the gold standard, a ranking exercise of paper patient cases, and a multicriterion decision analysis exercise. These data formed the basis for developing the classification criteria, which were tested in an independent data set. Results The entry criterion for the new classification criteria requires the occurrence of at least 1 episode of peripheral joint or bursal swelling, pain, or tenderness. The presence of MSU crystals in a symptomatic joint/bursa (i.e., synovial fluid) or in a tophus is a sufficient criterion for classification of the subject as having gout, and does not require further scoring. The domains of the new classification criteria include clinical (pattern of joint/bursa involvement, characteristics and time course of symptomatic episodes), laboratory (serum urate, MSU‐negative synovial fluid aspirate), and imaging (double‐contour sign on ultrasound or urate on dual‐energy computed tomography, radiographic gout‐related erosion). The sensitivity and specificity of the criteria are high (92% and 89%, respectively). Conclusion The new classification criteria, developed using a data‐driven and decision analytic approach, have excellent performance characteristics and incorporate current state‐of‐the‐art evidence regarding gout.
Desiderata for computable representations of electronic health records-driven phenotype algorithms
Mo, Huan , Thompson, William K. , Rasmussen, Luke V. , Pacheco, Jennifer A. , Jiang, Guoqian , Kiefer, Richard C. , Zhu, Qian , Xu, Jie , Montague, Enid , Mentch, Frank , Ni, Yizhao , Wehbe, Firas , Peissig, Peggy , Tromp, Gerard , Larson, Eric B. , Pathak, Jyotishman , Denny, Joshua C. , Speltz, Peter, Jarvik, Gail P. , Bejan, Cosmin A, Borthwick, Kenneth M., Kitchner, Terrie, Roden, Dan M. , Bejan, Cosmin A. , Kiefer, Richard, Carrell, David , Lingren, Todd , Chute, Christopher G. , Kho, Abel , Bejan, Cosmin A, Williams, Marc S , Roden, Dan M. , Harris, Paul A. , Denny, Joshua C , Jarvik, Gail P , Rasmussen, Luke V , Pacheco, Jennifer A

Mayo Clinic

Journal of the American Medical Informatics Association | September 6, 2015 | Volume: 22 | Issue: 6 | Pages: 1220-1230

10.1093/jamia/ocv112 | PMID 26342218 Get It

AbstractBackground Electronic health records (EHRs) are increasingly used for clinical and translational research through the creation of phenotype algorithms. Currently, phenotype algorithms are most commonly represented as noncomputable descriptive documents and knowledge artifacts that detail the protocols for querying diagnoses, symptoms, procedures, medications, and/or text-driven medical concepts, and are primarily meant for human comprehension. We present desiderata for developing a computable phenotype representation model (PheRM).Methods A team of clinicians and informaticians reviewed common features for multisite phenotype algorithms published in PheKB.org and existing phenotype representation platforms. We also evaluated well-known diagnostic criteria and clinical decision-making guidelines to encompass a broader category of algorithms.Results We propose 10 desired characteristics for a flexible, computable PheRM: (1) structure clinical data into queryable forms; (2) recommend use of a common data model, but also support customization for the variability and availability of EHR data among sites; (3) support both human-readable and computable representations of phenotype algorithms; (4) implement set operations and relational algebra for modeling phenotype algorithms; (5) represent phenotype criteria with structured rules; (6) support defining temporal relations between events; (7) use standardized terminologies and ontologies, and facilitate reuse of value sets; (8) define representations for text searching and natural language processing; (9) provide interfaces for external software algorithms; and (10) maintain backward compatibility.Conclusion A computable PheRM is needed for true phenotype portability and reliability across different EHR products and healthcare systems. These desiderata are a guide to inform the establishment and evolution of EHR phenotype algorithm authoring platforms and languages.
Genome-Wide Association Study of Prostate Cancer–Specific Survival
Szulkin, Robert , Whitington, Thomas, Aly, Markus , Grönberg, Henrik , Eeles, Rosalind A. , Easton, Douglas F. , Olama, Ali Amin Al , Benlloch, Sara, Muir, Kenneth , Giles, Graham G. , Southey, Melissa C. , FitzGerald, Liesel M. , Henderson, Brian E., Schumacher, Fredrick R. , Haiman, Christopher A. , Sipeky, Csilla , Tammela, Teuvo L.J. , Nordestgaard, Børge G. , Travis, Ruth C. , Neal, David E. , Donovan, Jenny , Hamdy, Freddie C. , Pashayan, Nora , Stanford, Janet L. , Thibodeau, Stephen N. , McDonnell, Shannon K. , Schaid, Daniel J. , Maier, Christiane, Vogel, Walther , Luedeke, Manuel, Herkommer, Kathleen , Kibel, Adam S. , Lubiński, Jan , Kluźniak, Wojciech , Cannon‐Albright, Lisa , Brenner, Hermann , Herrmann, Volker, Holleczek, Bernd , Sellers, Thomas A. , Lim, Hui-Yi, Kaneva, Radka , Mitev, Vanio , Teixeira, Manuel R. , Paulo, Paula , Maia, Sofia , Pandha, Hardev , Michael, Agnieszka , Batra, Jyotsna , Clements, Judith A. , BioResource, on behalf of the Australian Prostate Cancer, Albanes, Demetrius, Andriole, Gerald L. , Berndt, Sonja I., Gapstur, Susan M. , Giovannucci, Edward L. , Ma, Jing , Mondul, Alison M. , Stampfer, Meir J. , Stevens, Victoria L. , Weinstein, Stephanie J. , Trichopoulou, Antonia , Bueno-de-Mesquita, Bas H., Tjønneland, Anne , Cox, David G. , Mæhle, Lovise, Schleutker, Johanna , Lindström, Sara , Karlsson, Robert , Kote‐Jarai, Zsofia , Key, Tim , Pharoah, Paul D.P. , Khaw, Kay‐Tee , Cybulski, Cezary , Park, Jong Y. , Slavov, Chavdar , Spurdle, Amanda B. , Kierzek, Andrzej , BioResource, on behalf of the Australian Prostate Cancer, Berndt, Sonja I. , Chanock, Stephen Jacob , Hunter, David J. , Kraft, Peter , Marchand, Loı̈c Le , Penney, Kathryn , Wiklund, Fredrik E. , Giles, Graham G , Teixeira, Manuel R , Eeles, Rosalind A , Southey, Melissa C , Tjønneland, Anne , Donovan, Jenny L , Muir, Kenneth , Schleutker, Johanna , Travis, Ruth C , Pashayan, Nora , Cannon-Albright, Lisa A , Michael, Agnieszka , Brenner, Hermann , Batra, Jyotsna , Clements, Judith , Lubinski, Jan , McDonnell, Shannon K

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | August 25, 2015 | Volume: 24 | Issue: 11 | Pages: 1796-1800

10.1158/1055-9965.epi-15-0543 | PMID 26307654 Get It

Abstract Background: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical. Methods: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR). Results: We observed no significant association between genetic variants and prostate cancer survival. Conclusions: Common genetic variants with large impact on prostate cancer survival were not observed in this study. Impact: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes. Cancer Epidemiol Biomarkers Prev; 24(11); 1796–800. ©2015 AACR.
Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method
Espinel‐Ingroff, Ana , Carver, Peggy L. , Chen, S. C.-A., Eschenauer, Gregory , Getsinger, Diane, Govender, Nelesh P. , Grancini, Anna, Kidd, Sarah , Klinker, Kenneth , Kubin, Christine J. , Morris, Arthur J. , Peláez, Teresa, Quindós, Guillermo , Sánchez, F , Wengenack, Nancy L. , Solé, N. Borrell, Echeverría, J. , Esperalba, Juliana , Pedrosa, E. Gómez-G. de la, Linares, María José Pedraja, Marco, Francesc , Merino, Paloma , Pemán, Javier , Molino, Luisa Pérez del, Mayans, E. Roselló, Calvo, Carmen Rubio, Pipaón, Maite Ruiz Pérez de, Yagüe, Genoveva, García‐Effrón, Guillermo , Guinea, Jesús , Perlin, David S. , Sanguinetti, Maurizio , Shields, Ryan K. , Turnidge, John , Govender, N P , Quindós, G , Guinea, J , Álvarez-Fernández, Maximiliano , Cantón, Rafael , Chen, S. C.- A., González, Gloria María , Hanson, Kimberly E. , Kus, Julianne V. , Lockhart, Shawn R. , Meletiadis, Joseph , Rodríguez‐Iglesias, Manuel , Shoham, Shmuel , Pedrosa, Elia Gómez G. de la , García, Inmaculada García , Sánchez-Reus, F , Sanguinetti, M , Peman, J , Kidd, Sarah E

Mayo Clinic

Antimicrobial Agents and Chemotherapy | August 18, 2015 | Volume: 59 | Issue: 11 | Pages: 6725-6732

10.1128/aac.01250-15 | PMID 26282428 Get It

ABSTRACTNeither breakpoints (BPs) nor epidemiological cutoff values (ECVs) have been established forCandidaspp. with anidulafungin, caspofungin, and micafungin when using the Sensititre YeastOne (SYO) broth dilution colorimetric method. In addition, reference caspofungin MICs have so far proven to be unreliable.Candidaspecies wild-type (WT) MIC distributions (for microorganisms in a species/drug combination with no detectable phenotypic resistance) were established for 6,007Candida albicans, 186C. dubliniensis, 3,188C. glabratacomplex, 119C. guilliermondii, 493C. krusei, 205C. lusitaniae, 3,136C. parapsilosiscomplex, and 1,016C. tropicalisisolates. SYO MIC data gathered from 38 laboratories in Australia, Canada, Europe, Mexico, New Zealand, South Africa, and the United States were pooled to statistically define SYO ECVs. ECVs for anidulafungin, caspofungin, and micafungin encompassing ≥97.5% of the statistically modeled population were, respectively, 0.12, 0.25, and 0.06 μg/ml forC. albicans, 0.12, 0.25, and 0.03 μg/ml forC. glabratacomplex, 4, 2, and 4 μg/ml forC. parapsilosiscomplex, 0.5, 0.25, and 0.06 μg/ml forC. tropicalis, 0.25, 1, and 0.25 μg/ml forC. krusei, 0.25, 1, and 0.12 μg/ml forC. lusitaniae, 4, 2, and 2 μg/ml forC. guilliermondii, and 0.25, 0.25, and 0.12 μg/ml forC. dubliniensis. Species-specific SYO ECVs for anidulafungin, caspofungin, and micafungin correctly classified 72 (88.9%), 74 (91.4%), 76 (93.8%), respectively, of 81Candidaisolates with identifiedfksmutations. SYO ECVs may aid in detecting non-WT isolates with reduced susceptibility to anidulafungin, micafungin, and especially caspofungin, since testing the susceptibilities ofCandidaspp. to caspofungin by reference methodologies is not recommended.
Abstract 1475: Therapeutic responses in a novel patient-derived xenograft mouse model for rare acinar cell pancreatic carcinoma
Mathias, Adam , Dawson, Louis K., Durham, William F., Meshaw, Kenneth A., Mullin, Robert J., Synnott, Aidan J., Paz‐Fumagalli, Ricardo , Krishna, Murli , Hoff, Daniel D. Von , Small, Daniel L., Colón‐Otero, Gerardo , Copland, John A. , Marlow, Laura A.

Mayo Clinic

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 1475-1475

10.1158/1538-7445.am2015-1475 Get It

Abstract Acinar cell carcinoma of the pancreas (ACC) is an uncommon malignancy, accounting for less than 1% of all pancreatic neoplasms. Because of its rarity, only a few retrospective studies are available to help guide management. We previously reported the case of a patient with metastatic ACC who achieved prolonged survival with doxorubicin as a result of personalized treatment designed in part on the basis of molecular and in-vitro data collected on analysis of the tumor and primary cells in culture developed from the liver metastasis. We now report the characterization of a patient derived xenograft (PDX) mouse model originating from this patient's ACC liver metastasis tissue. Antitumor activity of multiple drugs (5-FU, irinotecan, oxaliplatin, gemcitabine, bevacizumab, erlotinib, doxorubicin and imatinib) used as single agent therapy is demonstrated. Of the targeted and cytotoxic therapies used, oxaliplatin produced a dramatic and prolonged response to therapy even after withdrawal of treatment. Bevacizumab produced a significant response, as well. Serum lipase and tissue amylase levels correlated with the antitumor response to therapy. Thus, we have developed and characterized an ACC PDX model that may be used in drug discovery for the treatment of this rare cancer for which no standard of care exists. Note: This abstract was not presented at the meeting. Citation Format: Laura A. Marlow, Adam C. Mathias, Louis K. Dawson, William F. Durham, Kenneth A. Meshaw, Robert J. Mullin, Aidan J. Synnott, Ricardo Paz-Fumagalli, Murli Krishna, Daniel Von Hoff, Daniel L. Small, Gerardo Colon-Otero, John A. Copland. Therapeutic responses in a novel patient-derived xenograft mouse model for rare acinar cell pancreatic carcinoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1475. doi:10.1158/1538-7445.AM2015-1475
Abstract 1458: Characterization of novel thyroid PDX models and their response to combination therapies
Mathias, Adam , Dawson, Louis K., Durham, William F., Meshaw, Kenneth A., Mullin, Robert J., Small, Daniel L., Synnott, Aidan J., Milosevic, Dragana , Netzel, Brian C., Grebe, Stefan K., Wu, Kevin J. , Smallridge, Robert C., Copland, John A. , Marlow, Laura A.

Mayo Clinic

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 1458-1458

10.1158/1538-7445.am2015-1458 Get It

Abstract Patient derived xenografts (PDX) mouse models for many types of cancer have demonstrated therapeutic responses similar to those seen in patients. Thus, resected patient tumor tissue directly implanted into immune compromised mice followed by therapy and tumor growth analysis is thought to be the closest preclinical model to predict patient therapeutic responses. To date, few models are available for the different histotypes of thyroid cancer derived from follicular thyrocytes; these include papillary, follicular, Hurthle cell, squamous and anaplastic thyroid carcinoma. We have developed eight PDX models in athymic nude mice representing all of these subtypes. The models have been extensively characterized for mutational status (i.e. BRAF, telomerase, RAS, PTEN, TP53, RB, etc) as well as validation by short tandem repeat (STR) analysis to match that of the originating patient tumor tissue. Squamous and anaplastic thyroid cancers are rare tumor types with no FDA approved therapies. Each model demonstrated their own unique responses to radiation, cytotoxic or molecular targeted therapies such as doxorubicin, sorafenib (tyrosine kinase inhibitor), cisplatin, paclitaxel, sunitinib (tyrosine kinase inhibitor), erlotinib (EGFR inhibitor), trametinib (MEK inhibitor) and vemurafenib (BRAF inhibitor). We expect that these models may provide useful in vivo models for thyroid cancer research as well as models for therapeutic guidance based upon histotype, mutational status and response to therapies. Citation Format: Laura A. Marlow, Adam C. Mathias, Louis K. Dawson, William F. Durham, Kenneth A. Meshaw, Robert J. Mullin, Daniel L. Small, Aidan J. Synnott, Dragana Milosevic, Brian C. Netzel, Stefan K. Grebe, Kevin Wu, Robert C. Smallridge, John A. Copland. Characterization of novel thyroid PDX models and their response to combination therapies. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1458. doi:10.1158/1538-7445.AM2015-1458
Accuracy of the ABC/2 Score for Intracerebral Hemorrhage
Webb, Alastair J.S. , Ullman, Natalie , Morgan, Tim C., Muschelli, John , Kornbluth, Joshua , Awad, Issam A. , Rosenblum, Michael , Ziai, Wendy , Zuccarrello, Mario, Aldrich, François, John, Sayona , Harnof, Sagi , Lopez, George Α. , Broaddus, William C. , Wijman, Christine A.C., Vespa, Paul , Bullock, Ross, Haines, Stephen J. , Cruz‐Flores, Salvador , Tuhrim, Stan, Hill, Michael D. , Narayan, Raj K. , Hanley, Daniel F. , Tayal, Ashis , Díaz, Alberto Torres, Hoffer, Alan , Moheet, Asma , Agarwal, Sachin , Markowski, Mason, Rosenthal, Guy , Kureshi, Inam, Varelas, Panayiotis N. , Pinto, Pedro Telles Cougo, Camarata, Paul J. , Helms, Ann , Shahi, Kavian, Sinclair, David, Gizzi, Martin , LeDoux, David, Torbey, Michel , Cockroft, Kevin M. , Antezana, David, Margalit, Nevo, Crabtree, H. Mark, Lovick, Darren, Weaver, Michael, Leonardo, Jody, Ardelt, Agnieszka, Csiba, László , Wartenberg, Katja E. , Bösel, Julian , Adams, Harold P. , Hobohm, Carsten , Kerz, Thomas , Wechsler, Lawrence R. , Gardner, Paul A. , Decker, David A., Gonzales, Nicole R. , Caron, Jean-Louis, Hall, Christiana E., Ansari, Safdar , Luft, Andreas R. , Graham, R. Scott, Tucker, Kristi, Webb, Alastair Js , Mayo, Stephen L. , Martí‐Fábregas, Joan , Seder, David B. , Freeman, William D. , Lazaridis, Christos , LeDoux, David, Latorre, Julius Gene , Venkatasubramanian, Chitra , Jallo, Jack , Reinert, Michael , Butcher, Kenneth , Adeoye, Opeolu M , Testai, Fernando D. , Bulters, Diederik , Caron, Jean-Louis R., Arikán, Fuat , Hill, Michael D , Hanley, Daniel F , Lopez, George

Mayo Clinic

Stroke | August 5, 2015 | Volume: 46 | Issue: 9 | Pages: 2470-2476

10.1161/strokeaha.114.007343 | PMID 26243227 Get It

Background and Purpose— The ABC/2 score estimates intracerebral hemorrhage (ICH) volume, yet validations have been limited by small samples and inappropriate outcome measures. We determined accuracy of the ABC/2 score calculated at a specialized reading center (RC-ABC) or local site (site-ABC) versus the reference-standard computed tomography–based planimetry (CTP). Methods— In Minimally Invasive Surgery Plus Recombinant Tissue-Type Plasminogen Activator for Intracerebral Hemorrhage Evacuation-II (MISTIE-II), Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR-IVH) and CLEAR-III trials. ICH volume was prospectively calculated by CTP, RC-ABC, and site-ABC. Agreement between CTP and ABC/2 was defined as an absolute difference up to 5 mL and relative difference within 20%. Determinants of ABC/2 accuracy were assessed by logistic regression. Results— In 4369 scans from 507 patients, CTP was more strongly correlated with RC-ABC ( r 2 =0.93) than with site-ABC ( r 2 =0.87). Although RC-ABC overestimated CTP-based volume on average (RC-ABC, 15.2 cm 3 ; CTP, 12.7 cm3), agreement was reasonable when categorized into mild, moderate, and severe ICH (κ=0.75; P <0.001). This was consistent with overestimation of ICH volume in 6 of 8 previous studies. Agreement with CTP was greater for RC-ABC (84% within 5 mL; 48% of scans within 20%) than for site-ABC (81% within 5 mL; 41% within 20%). RC-ABC had moderate accuracy for detecting ≥5 mL change in CTP volume between consecutive scans (sensitivity, 0.76; specificity, 0.86) and was more accurate with smaller ICH, thalamic hemorrhage, and homogeneous clots. Conclusions— ABC/2 scores at local or central sites are sufficiently accurate to categorize ICH volume and assess eligibility for the CLEAR-III and MISTIE III studies and moderately accurate for change in ICH volume. However, accuracy decreases with large, irregular, or lobar clots. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: MISTIE-II NCT00224770; CLEAR-III NCT00784134.
Abstract 4629: Multiple myeloma susceptibility loci examined in African and European ancestry populations
Rand, Kristin A. , Song, Chi , Déan, Eric, Serie, Daniel, Curtin, Karen , Hazelett, Dennis J. , Hwang, Amie E. , Sheng, Xin , Stram, Alex , Huff, Carol Ann , Bernal‐Mizrachi, Leon , Roos, Anneclaire De, Pawlish, Karen , Peters, Edward , Bock, Catherine, Conti, David V. , Zimmerman, Todd M., Huntsman, Scott , Graff, John, Mehta, Jayesh, Janakiraman, Nalini, Severson, Richard K., Brown, Elizabeth E. , Kolonel, Laurence N. , Henderson, Brian E., Spinelli, John J., Zonder, Jeffrey A. , Camp, Nicola J. , Vachon, Celine M. , Stram, D. O., Haiman, Christopher A. , Berg, David Van Den , Tomasson, Michael H. , Ailawadhi, Sikander , Singhal, Seema , Colditz, Graham A. , Chanock, Stephen Jacob , Lieber, Michael R. , Klein, Eric A. , Brooks‐Wilson, Angela , Rajkumar, S. Vincent , Slager, Susan L. , Giles, Graham G. , Chiu, Brian C.‐H. , Anderson, Kenneth C. , Orlowski, Robert Z. , Lonial, Sagar , Vachon, Celine M. , Ziv, Elad , Cozen, Wendy , Hazelett, Dennis J , Conti, David V

Mayo Clinic

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 4629-4629

10.1158/1538-7445.am2015-4629 Get It

Abstract Genome-wide association studies (GWAS) of multiple myeloma (MM) in Northern Europeans have identified seven novel risk loci (2p23.3, 3p22.1, 3q26.2, 6p21.33, 7p15.3, 17p11.2, 22q13.1). We performed a multiethnic meta-analysis of these regions in 1,274 MM patients and 1,486 controls of European ancestry (EA) and 1,049 MM patients and 7,080 controls of African ancestry (AA), leveraging the differential linkage-disequilibrium of these populations in order to better localize the putative functional variants. We observed directionally consistent effects for all seven index SNPs in both populations, with four significantly associated (p&lt;0.05) with risk in EAs (3p22.1, 7p15.3, 17p11.2, 22q13.1), and two significantly associated with risk in AAs (7p15.3 and 22q13.1). In a fixed effects meta-analysis of six regions (excluding the HLA region on chromosome 6), variation in five of the regions (2p33.3, 3p22.1, 7p15.3, 17p11.2, 22q13.1) had statistically significant associations with risk (Table 1). In one region, the index variant had the strongest association [rs4487645 at 7p15.3, (OR = 1.30, p = 8.7×10−8)]. Five of the six most significantly associated variants identified in the multiethnic analyses overlapped with biologically relevant features indicating regulatory activity based on CD20+ (B lymphocyte) cells, showing evidence of potential function; those included a missense variant in (17p11.2, rs34562254, Pro251Leu) in TNFRSF13B, which encodes a lymphocyte-specific protein in the tumor necrosis factor receptor family that interacts with the NF-kb pathway. Our study shows that these regions are important in MM risk across ethnicities and further supports the use of multiple ethnic groups in genetic studies to enhance identification of risk variants. Table 1.Most significant associations for each region in the multiethnic meta-analysis.Individuals of European AncestryIndividuals of African AncestryMulitethnic Metar2 with IndexcCHRSNPRAaFreqbORP-valueFreqbORP-valueORP-valueP-het2rs732075G0.591.222.0×10−30.621.122.0×10−21.162.6×10−40.280.09/0.283rs73069394A0.191.243.0×10−30.621.181.5×10−21.201.3×10−50.550.77/0.963rs12637184G0.761.136.0×10−20.921.192.7×10−11.151.0×10−20.640.94/1.007rs4487645C0.671.237.0×10−40.891.485.5×10−51.308.7×10−80.07-d17rs34562254A0.121.452.4×10−50.131.212.2×10−31.312.5×10−60.120.33/0.9022rs139400T0.491.224.0×10−40.531.172.1×10−31.191.2×10−60.630.63/0.96aRisk allelebFrequency of the risk allele in European and African ancestry studiescr2 metrics based on 1000 Genomes Project AFR/EUR populationsdIndex SNP Citation Format: Kristin A. Rand, Chi Song, Eric Dean, Daniel Serie, Karen Curtin, Dennis Hazelett, Amie E. Hwang, Xin Sheng, Alex Stram, David J. Van Den Berg, Carol Ann Huff, Leon Bernal-Mizrachi, Michael H. Tomasson, Sikander Ailawadhi, Anneclaire De Roos, Seema Singhal, Karen Pawlish, Edward Peters, Catherine Bock, David V. Conti, Graham Colditz, Todd Zimmerman, Scott Huntsman, John Graff, African Ancestry Prostate Cancer GWAS Consortium,African Ancestry Breast Cancer GWAS Consortium, Stephen J. Chanock, Michael Lieber, Jayesh Mehta, Eric A. Klein, Nalini Janakiraman, Richard K. Severson, Angela R. Brooks-Wilson, Vincent Rajkumar, Elizabeth E. Brown, Laurence Kolonel, Susan Slager, Brian E. Henderson, Graham G. Giles, John J. Spinelli, Brian Chiu, Kenneth C. Anderson, Jeffrey Zonder, Robert Z. Orlowski, Sagar Lonial, Nicola Camp, Celine Vachon, Elad Ziv, Dan O. Stram, Christopher A. Haiman, Wendy Cozen. Multiple myeloma susceptibility loci examined in African and European ancestry populations. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4629. doi:10.1158/1538-7445.AM2015-4629
Abstract 2417: Characterization of novel patient derived melanoma xenografts and cell lines in response to targeted therapies
Harris, Antoneicka L., Mathias, Adam , Dawson, Louis K., Durham, William F., Meshaw, Kenneth A., Mullin, Robert J., Small, Daniel L., Synnott, Aidan J., Wu, Kevin J. , Milosevic, Dragana , Netzel, Brian C., Grebe, Stefan K., Copland, John A. , Marlow, Laura A. , Markovic, Svetomir N.

Mayo Clinic

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 2417-2417

10.1158/1538-7445.am2015-2417 Get It

Abstract The success of clinical trials for patients with malignant melanoma (MM) designed from the “promising” results using pre-clinical models is minimal. With its increase in incidence, there is a dire need to develop both pre-clinical models comparable to clinical practice that have the capability to translate from bench-to-bedside and novel therapeutic agents for this life-threatening form of skin cancer. To address this concern, we have developed a panel of pre-clinical MM models including patient matched cell lines, patient cell-line derived xenograft models and patient tumor tissue-derived xenograft models. Patient derived xenograft (PDX) models are purported to most closely replicate a patient's response to therapy. Since the development of patient-derived cell lines and tumors grown in mice were more efficacious, their genetic, phenotypic, and therapeutic responses were compared to those of their corresponding patient-matched PDX model. Each model was molecularly characterized to confirm a match to that of the originating patient tumor tissue via protein immunohistochemistry (IHC), mRNA quantitative polymerase chain reaction (qPCR), DNA short tandem repeat (STR) analysis, and Sanger sequencing. Each pre-clinical model provided a genetic match to their respective patient tumor sample. All pre-clinical models were positive for the melanoma-specific markers (S-100 beta, HMB-45, and Melan-A) confirming a melanoma phenotype. Soft agar studies and tumor growth of our PDX and patient cell-line derived xenograft models confirmed tumorigenicity within our models providing the foundation to perform therapeutic studies. Mutation status data (i.e. BRAF, RAS), patient therapeutic clinical history and oncogene overexpression analysis (pERK, pAKT, PI3K, pmTOR, etc.) provide the platform and rationale behind the use of specific therapeutic agents per model. BRAF, NRAS and KRAS mutations were identified along with elevated pERK, pAKT and pmTOR in the models. Targeted therapies (trametinib/MEK inhibitor; vemurafenib/BRAF inhibitor; MK-2206/pAKT inhibitor; and everolimus/mTOR inhibitor) demonstrated dose dependent inhibition of cell proliferation in each of the models based upon oncogenic expression or mutations. In vivo experiments are in progress, which will allow comparison of the three models. The next steps include combination therapy to identify antitumor synergy targeting oncogenic signaling pathways. Citation Format: Antoneicka L. Harris, Laura Marlow, Adam Mathias, Louis Dawson, William Durham, Kenneth Meshaw, Robert Mullin, Daniel Small, Aidan Synnott, Kevin Wu, Dragana Milosevic, Brian Netzel, Stefan Grebe, Svetomir Markovic, John Copland. Characterization of novel patient derived melanoma xenografts and cell lines in response to targeted therapies. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2417. doi:10.1158/1538-7445.AM2015-2417
Three-Dimensional Rotational Angiography-Guided Stent Placement for Treatment of Acquired Supravalvar Aortic Stenosis
Anderson, Jason H. , Fetterly, Kenneth A. , Taggart, Nathaniel W. , Taggart, Nathaniel W , Anderson, Jason

Mayo Clinic

Circulation | August 3, 2015 | Volume: 132 | Issue: 5 | Pages: 455-456

10.1161/circulationaha.115.017612 | PMID 26240266 Get It